The Albany Gazette - New to The Street Signs NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) to 12-Part National Broadcast Series Including T.V. Network Features, Earned Media, Commercials, and Iconic Outdoor Billboards

NYSE - LSE

RBGPF	-19.57%	69	$
NGG	-2.08%	84.27	$
CMSD	-0.2%	23.04	$
RYCEF	-8.26%	15.85	$
BCE	-0.21%	23.9	$
VOD	-3.03%	15.19	$
RELX	0.89%	37.07	$
GSK	-2.19%	56.12	$
CMSC	-0.31%	22.66	$
BTI	-4.07%	54.83	$
RIO	-2.16%	97.72	$
BCC	-1.84%	82.45	$
JRI	-0.61%	13.05	$
AZN	-2.51%	195.78	$
BP	1.72%	45.91	$

New to The Street Signs NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) to 12-Part National Broadcast Series Including T.V. Network Features, Earned Media, Commercials, and Iconic Outdoor Billboards

BOULEVARD 30.07.2025

New to The Street Signs NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) to 12-Part National Broadcast Series Including T.V. Network Features, Earned Media, Commercials, and Iconic Outdoor Billboards

NEW YORK CITY, NEW YORK / ACCESS Newswire / July 30, 2025 / New to The Street, the nation's premier financial media platform for emerging public companies, proudly announces a major media partnership with NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI). Under this agreement, NeOnc will be featured in a 12-part national broadcast series, with exclusive monthly interviews airing on Bloomberg Television and Fox Business Network. The series will also include earned media distribution, commercial rotation across national networks, and outdoor billboard campaigns in the most visible financial corridors in the U.S.

Text size:

This partnership launches at a pivotal time for NeOnc Technologies, following two significant corporate milestones:

The signing of a Letter of Intent to acquire breakthrough intellectual property (IP) for brain cancer treatment, positioning the company at the forefront of neuro-oncology innovation;
The execution of a $50 million definitive strategic partnership with Quazar Investment, accelerating NeOnc's operational and clinical development roadmap.

Breakthrough Science Meets Breakthrough Exposure

The integrated media campaign includes:

12 Long-Form Network Broadcast Interviews from the Nasdaq and NYSE studios on Bloomberg TV and Fox Business as sponsored programming.
More than 300 Monthly Commercial Spots across targeted investor and innovation-focused time blocks.
Earned Media Coverage on major U.S. networks via NewsOut™, including CBS, NBC, and ABC affiliates.
Iconic Billboard Placements in Times Square (Nasdaq Tower and Reuters Boards), NYC Financial District shelters, and premium taxi tops.
Digital Amplification via YouTube and social platforms:
- New to The Street TV Channel: youtube.com/@NewtotheStreetTV
- NewsOut Channel: youtube.com/@newsoutchannel

Executive Commentary

"NeOnc is entering a new era, not only in terms of medical science but also visibility in the public markets. Their latest IP acquisition and $50 million partnership with Quazar reflect serious momentum," said Vince Caruso, Founder and CEO of New to The Street. "We're proud to provide a media platform that matches their global ambitions and innovations with real-world distribution, every month."

About NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI)

NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company's NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas.

NeOnc's lead therapeutics, NEO100™ and NEO212™, are currently in Phase II human clinical trials and advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California, consisting of issued patents and pending applications related to NEO100, NEO212, and other candidates from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
To learn more, visit https://www.neonc.com.

About New to The Street

Since 2009, New to The Street has been a leading force in financial media, showcasing public and private companies through its unmatched mix of national television broadcasts, digital syndication, and social media reach. With over 3.2 million subscribers on the New to The Street TV YouTube channel and a combined following of more than 511,000 across LinkedIn, Facebook, Instagram, and X, the platform delivers consistent visibility to investors, industry leaders, and the general public.

New to The Street offers more linear "real TV" broadcast distribution than any other outlet in the space, with long-running placements across Bloomberg TV, Fox Business Network, and other national platforms. Its "Opportunities to Consider™" segments and in-depth executive interviews have become a trusted source for market-moving narratives, emerging growth stories, and thought leadership across finance, tech, biotech, and beyond.

Learn more: